Sanofi CEO: ‘Everybody gets access’ to potential coronavirus treatment if proven correct
Sanofi CEO Paul Hudson discusses the rapid progress being made in developing a coronavirus vaccine and moving the production of essential pharmaceutical supply from China to Europe.
Get all the latest news on coronavirus and more delivered daily to your inbox. Sign up here.
Continue Reading Below
Sanofi CEO Paul Hudson said Wednesday that the French drugmaker is working to ensure "everybody" has access to hydroxychloroquine, the anti-malaria drug that has been discussed as a potential treatment for the novel coronavirus, if it's proven to be an effective measure.
"On hydroxychloroquine, you know, we give it away free. It's our plan to make sure that we bring it, if it's proven to be correct, that everybody gets access to it," Hudson told FOX Business' Maria Bartiromo. "And I think not just us, but other makers as well should try and do their best to make sure nothing stops patients that need getting these medicines. We'll wait and see what the evidence is. It's just around the corner. Then we'll know definitively."
Sanofi produces a brand-named version of hydroxychloroquine called Plaquenil.
NEW CORONAVIRUS TEST DELIVERS RESULTS WITHIN 15 MINUTES
Hudson said studies are underway on its rheumatoid arthritis drug Kevzara and hydroxychloroquine, at Mount Sinai Hospital in New York City, Northwell Health in Long Island, New York, and across Europe to get evidence to show how the treatments work.